# Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.

Study · id `cardio:ct-nct03857256` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03857256](<https://clinicaltrials.gov/study/NCT03857256>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03857256

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 263 participants.

## Technical summary

Registry record NCT03857256. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-31 (actual); primary completion 2021-08-31 (actual). Results posted on 2024-01-16.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 263 participants (enrolled count; ClinicalTrials.gov record NCT03857256, source copy `cardio:ctgov-nct03857256-2024-01-16`, retrieved 2026-10-31)
- Started: 2019-05-31 (actual) (ClinicalTrials.gov record NCT03857256, source copy `cardio:ctgov-nct03857256-2024-01-16`, retrieved 2026-10-31)
- Primary completion: 2021-08-31 (actual) (ClinicalTrials.gov record NCT03857256, source copy `cardio:ctgov-nct03857256-2024-01-16`, retrieved 2026-10-31)
- Completion: 2021-12-31 (actual) (ClinicalTrials.gov record NCT03857256, source copy `cardio:ctgov-nct03857256-2024-01-16`, retrieved 2026-10-31)
- Results first posted: 2024-01-16 (ClinicalTrials.gov record NCT03857256, source copy `cardio:ctgov-nct03857256-2024-01-16`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT03857256, source copy `cardio:ctgov-nct03857256-2024-01-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03857256-2024-01-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.
- Acronym: BetAvena
- Condition: Hyperlipidemias
- Intervention (Drug): CP105F
- Intervention (Drug): Placebo
- Lead sponsor: Montreal Heart Institute
- Lead sponsor class: OTHER
- Collaborator: Ceapro Inc.
- Collaborator class: INDUSTRY
- Collaborator: The Montreal Health Innovations Coordinating Center (MHICC)
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Montreal Heart Institute (`cardio:org-montreal-heart-institute`)
- Registry lists this organization as a collaborator: The Montreal Health Innovations Coordinating Center (MHICC) (`cardio:org-the-montreal-health-innovations-coordinating-center-mhicc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Supplementation with a β-glucan tablet has no effect on hyperlipidemia: a randomized, placebo-controlled clinical trial (`cardio:pubmed-37054888`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fe7fc86246ca305cc79a10741dbc33d7267a39cffcfcc0e7554cb57a8b5c8d74
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
